<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Investigational therapies for sickle cell disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Investigational therapies for sickle cell disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Investigational therapies for sickle cell disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Courtney Fitzhugh, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael R DeBaun, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2236658586"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The major causes of morbidity and mortality in sickle cell disease (SCD) are the acute and long-term consequences of ischemia-reperfusion injury of the organs, leading to cerebral infarcts; heart, lung, and kidney disease; pain that can be severe and debilitating; and other complications.</p><p><a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> is the primary therapy to prevent these complications in children and adults with Hb SS and Hb S beta<sup>0</sup> thalassemia. Hydroxyurea provides a myriad of well-documented clinical benefits, making it the first choice for children and adults with Hb SS and Hb S beta<sup>0</sup> thalassemia. However, hydroxyurea has limitations, and not all individuals with SCD benefit from therapy. Additional therapies are needed for those who cannot take hydroxyurea or for whom hydroxyurea or one of the other disease-modifying therapies is ineffective. (See  <a class="medical medical_review" href="/d/html/126298.html" rel="external">"Disease-modifying therapies to prevent pain and other complications of sickle cell disease"</a>.)</p><p>This topic reviews potential therapies for SCD that are in development or undergoing clinical investigation, including their rationale, preclinical data, and information from early clinical trials. It also discusses when these approaches should be considered and when patients should be referred to be considered for therapy with a curative intent.</p><p>Separate topic reviews discuss existing management options in SCD including routine evaluations and treatments, <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> and other disease-modifying therapies, transfusions, and hematopoietic stem cell transplantation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management overview</strong> – (See  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comprehensive care for children</strong> – (See  <a class="medical medical_review" href="/d/html/14519.html" rel="external">"Sickle cell disease in infancy and childhood: Routine health care maintenance and anticipatory guidance"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain management</strong> – (See  <a class="medical medical_review" href="/d/html/7144.html" rel="external">"Acute vaso-occlusive pain management in sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydroxyurea</strong> – (See  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion</strong> – (See  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stem cell transplantation and gene therapy </strong>– (See  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p></p><p class="headingAnchor" id="H1143466115"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H2947648758"><span class="h2">Timeline of drug development in SCD</span><span class="headingEndMark"> — </span>Since the initial report of SCD, there have been few approved disease-modifying therapies, with the first drug, <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, approved over 80 years later. The timeline of new SCD therapies has accelerated during the previous two decades, with the following history:</p><p class="bulletIndent1"><span class="glyph">●</span>1910 – SCD first reported</p><p class="bulletIndent1"><span class="glyph">●</span>1998 – First drug approved for SCD treatment (<a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>2017 to 2019 – Three additional therapies approved (L-glutamine in 2017; <a class="drug drug_general" data-topicid="126184" href="/d/drug information/126184.html" rel="external">crizanlizumab</a> and <a class="drug drug_general" data-topicid="126260" href="/d/drug information/126260.html" rel="external">voxelotor</a> in 2019)</p><p></p><p>More agents are being developed and are in early phase trials. (See <a class="local">'Pharmacologic therapies'</a> below.)</p><p class="headingAnchor" id="H533158675"><span class="h2">Limitations of available therapies</span><span class="headingEndMark"> — </span>The most common and debilitating complication experienced by individuals with SCD is acute vaso-occlusive pain. However, there are other risks for severe morbidity and early mortality due to chronic complications such as stroke, kidney failure, and cardiopulmonary disease [<a href="#rid1">1,2</a>]. Despite the remarkable efficacy of <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, there are limitations to its use, and many questions remain unanswered:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>– The efficacy of <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> in individuals with Hb SC and Hb S beta<sup>+</sup> thalassemia is unproven. Important clinical trial data have mostly included individuals with Hb SS and Hb S beta<sup>0</sup> thalassemia. (See  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease", section on 'Evidence for efficacy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety</strong> – <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> has limited use in individuals planning to have children. It typically is not used in females attempting to conceive due to presumed teratogenic effects, although definitive evidence of teratogenicity is lacking [<a href="#rid3">3</a>]. It typically is not used in males attempting conception due to its impact on sperm count, although it has no significant impact on spermatogenesis when started during the pre-pubertal period [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> reduces vaso-occlusive pain episodes, acute chest syndrome, and red blood cell transfusions by approximately 50 percent in adults with Hb SS and Hb S beta<sup>0</sup> thalassemia. However, some individuals will continue to have acute pain episodes, other vaso-occlusive events, or both, despite adherence to properly administered hydroxyurea. Morbidity and mortality remain high in adults with SCD, even when treated with hydroxyurea [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease", section on 'Survival and prognosis'</a>.)</p><p></p><p>The newer FDA-approved therapies may further reduce vaso-occlusive complications, improve anemia, and/or reduce hemolysis, but none of them have been demonstrated to abate progressive heart, lung, kidney, or central nervous system disease or to provide a cure for the disease. Additionally, some carry high costs and burdens such as the requirement for intravenous administration. (See  <a class="medical medical_review" href="/d/html/126298.html" rel="external">"Disease-modifying therapies to prevent pain and other complications of sickle cell disease", section on 'Disease-modifying medications'</a>.)</p><p>Regular blood transfusion therapy, with a goal to decrease the Hb S level &lt;30 percent or 50 percent, is indicated in some individuals, but transfusions also carry significant costs and burdens. (See <a class="local">'Transfusions'</a> below.)</p><p>New therapies and multi-modality approaches are needed to prevent acute vaso-occlusive pain episodes, attenuate progressive organ damage (including brain, heart, lung, and kidney), and increase life expectancy, as well as therapies that can be used in individuals with other compound heterozygous SCD (including sickle beta<sup>+ </sup>thalassemia and hemoglobin SC disease). Further, no disease-modifying therapy, other than monthly blood transfusion therapy, can be used for pregnant women, a period with the highest incidence rates of acute pain and acute chest syndrome [<a href="#rid7">7</a>]. As new therapies are being considered, strategies should be included that can be used during pregnancy.</p><p class="headingAnchor" id="H3622545963"><span class="h2">Categories of SCD therapies</span><span class="headingEndMark"> — </span>Therapies for SCD can be categorized as pharmacologic or curative.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic</strong> – Pharmacologic therapies are medications that must be taken on a regular basis. There are several steps in the vaso-occlusion process that can be targeted. Many of these are under investigation, as summarized in the discussions below. Examples include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fetal hemoglobin induction</strong> – (See <a class="local">'Increasing Hb F'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inhibiting sickle hemoglobin polymerization</strong> – (See <a class="local">'Reducing Hb S polymerization'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reducing interactions between sickle cells, neutrophils, and/or vasculature</strong> – (See <a class="local">'Decreasing cell adhesion'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Decreasing oxidative stress</strong> – (See <a class="local">'Decreasing oxidative stress (cathepsin B inhibitor, arginine)'</a> below.)</p><p></p><p class="bulletIndent1">In some cases it may be possible to target several of these processes simultaneously, which might produce additive or synergistic effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Curative</strong> – Curative therapy refers to hematopoietic stem cell transplant (HSCT), including standard allogeneic HSCT, alternative donor allogeneic HSCT, haploidentical transplant, and modified autologous HSCT using autologous hematopoietic stem cells (HSCs) that have been treated with gene therapy or gene editing techniques.</p><p></p><p class="bulletIndent1">We consider all HSCT therapies to be investigational in SCD because the optimal approach to their use remains unclear, especially for children. (See <a class="local">'Therapies with curative intent'</a> below and  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p></p><p class="headingAnchor" id="H633596835"><span class="h2">How to select and sequence therapies</span></p><p class="headingAnchor" id="H2328859135"><span class="h3">FDA-approved agents</span><span class="headingEndMark"> — </span>US Food and Drug Administration (FDA)-approved agents, along with indications for use, supporting data, and appropriate sequence, are summarized below and discussed in detail in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydroxyurea</strong><strong> </strong>– Should be offered to all adults and children with Hb SS and Hb S beta<sup>0</sup> thalassemia at nine months of age. (See  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>L-glutamine</strong> – May be offered to children ≥5 years or adults who continue to have pain episodes despite <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> or who cannot take hydroxyurea. (See  <a class="medical medical_review" href="/d/html/126298.html" rel="external">"Disease-modifying therapies to prevent pain and other complications of sickle cell disease", section on 'L-glutamine (pharmaceutical grade)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Crizanlizumab</strong> – May be offered to adolescents ≥16 years or adults who continue to have pain episodes despite <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> or who cannot take hydroxyurea. (See  <a class="medical medical_review" href="/d/html/126298.html" rel="external">"Disease-modifying therapies to prevent pain and other complications of sickle cell disease", section on 'Crizanlizumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Voxelotor</strong> – May be offered to children ≥4 years or adults who have symptomatic or severe anemia related to their SCD.</p><p></p><p class="headingAnchor" id="H387302233"><span class="h3">Transfusions</span><span class="headingEndMark"> — </span>Transfusions can be used to treat acute anemia or as prophylaxis against complications, as summarized briefly here and in detail separately. The goal of chronic (regular) transfusion therapy or exchange transfusions is to keep the percent of Hb S &lt;30 percent. (See  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Indications for transfusion'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute vaso-occlusive events</strong> – Transfusions are used in the acute setting for stroke, acute chest syndrome, multi-organ failure, symptomatic anemia, hepatic sequestration, or splenic sequestration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylaxis</strong> – Transfusions are used preoperatively and during pregnancy. Chronic transfusions are used for stroke prevention in at-risk individuals, and for certain other recurrent vaso-occlusive complications (eg, acute chest syndrome) if they continue despite <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> and the individual is eligible for therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain control</strong> – We consider a defined period of chronic transfusions (typically 6 to 12 months) in adolescents and adults with recurrent acute pain episodes that are not improved with disease-modifying therapy. Transfusion therapy is often coupled with mental health counseling for assessment of the presence and treatment of depression and anxiety. However, transfusions carry risks and burdens, as discussed separately. We agree with a 2020 guideline from the American Society of Hematology (ASH) that suggests monthly (regular) transfusions <strong>not</strong> be used as a <strong>first-line strategy</strong> to prevent or reduce recurrent acute pain episodes [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/128123.html" rel="external">"Transfusion in sickle cell disease: Management of complications including iron overload"</a>.)</p><p></p><p class="headingAnchor" id="H2840103316"><span class="h3">When to consider investigational therapies</span><span class="headingEndMark"> — </span>Individuals whose disease is well controlled with available therapies, who have good quality of life, and who wish to avoid the burdens and unknown risks of investigational therapies, may continue their current treatment. For others, the question of investigational therapies may be further explored.</p><p>Investigational therapies that have not been approved by the FDA or a comparable regulatory agency are administered as part of a clinical trial. FDA-approved therapies may be administered for an off-label indication that is considered investigational. The decision to participate in a clinical trial depends on what clinical trials are available at the time and the expert opinion of an SCD specialist.</p><p>Clinicians and patients should familiarize themselves with the details of the trial (or off-label use) before participating, including available alternatives, possible benefits, possible risks, and trial design and oversight. In some cases, individuals and their families may need to travel to specialized SCD centers that are conducting research to receive investigational therapies.</p><p>The risk-benefit calculation differs substantially between pharmacologic therapies, which can be discontinued if unhelpful or for side effects, versus curative therapies, which carry a much higher up-front risk and the possibility for cure. Considerations for each type of therapy are discussed below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic</strong> – Pharmacologic therapies include a number of drugs directed at various biologic targets to improve disease outcomes, typically focused on decreasing the incidence of acute vaso-occlusive pain (see <a class="local">'Pharmacologic therapies'</a> below). Our approach is to reserve investigational pharmacologic therapies for children and adults who want to participate in clinical trials and where the potential risk-benefit ratio favors trial participation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Curative</strong> – With improvement in overall care and use of <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, a disease modifying therapy, the overall survival in children up to age 18 with SCD living in high-income countries 99 percent [<a href="#rid9">9,10</a>]. In children with SCD, based on the high survival rate, coupled with poorly defined risk of death and long-term health effects of curative therapy, our approach is to reserve hematopoietic stem cell transplant (HSCT; myeloablative matched related donor transplant or non-myeloablative haploidentical donor transplant with post-transplant <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>) for children with cerebral infarcts (stroke or silent cerebral infarcts), or progressive heart, lung, or kidney disease that does not respond to disease-modifying therapy [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1">Adults with repetitive pain episodes, recurrent priapism events, persistent acute complications, cerebral infarcts, or progressive heart, lung, or kidney disease that does not respond to disease-modifying therapy should at least be informed about investigational curative therapies. (See <a class="local">'Overview of curative therapies'</a> below and  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p></p><p class="headingAnchor" id="H1055355816"><span class="h1">PHARMACOLOGIC THERAPIES</span><span class="headingEndMark"> — </span>Investigational therapies should be considered only as part of a clinical trial. Drug trials for the most part focus on painful episodes as an endpoint, although drugs that reduce vaso-occlusive pain may also reduce other vaso-occlusive complications. Resources for determining which trials are available as well as recruiting, entry criteria, and other aspects of trial oversight are limited. The clinicaltrials.gov website is the best resource for trial review. As noted below, referral to an expert center that conducts high-quality clinical trials in SCD, including curative therapies, may be the best approach to ensuring that patients and their families receive the most comprehensive and balanced information about available trials. (See <a class="local">'Overview of curative therapies'</a> below and  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p>General information about the types of strategies being explored is summarized in the following sections.</p><p class="headingAnchor" id="H4056787183"><span class="h2">Increasing Hb F</span><span class="headingEndMark"> — </span>Fetal hemoglobin (hemoglobin F [Hb F]) is comprised of alpha globin chains and gamma globin chains, which do not contain the sickle cell variant (present only in beta globin chains). Increases in Hb F reduce the proportion of sickle hemoglobin, and this reduction in turn reduces the abnormal polymerization of hemoglobin molecules. (See <a class="local">'Reducing Hb S polymerization'</a> below.)</p><p>Increasing Hb F was initially thought to be the primary mechanism of action of <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> in SCD, although other contributing mechanisms have subsequently been proposed. (See <a class="local">'FDA-approved agents'</a> above and  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease", section on 'Mechanism of action'</a>.)</p><p>Other drugs are under development to increase Hb F by a variety of mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epigenetic changes</strong> – Drugs that de-repress gamma globin gene expression via epigenetic mechanisms (deoxyribonucleic acid [DNA] methyltransferase [DNMT] inhibitors, histone deacetylase [HDAC] inhibitors) [<a href="#rid12">12-17</a>]. Of these, <a class="drug drug_general" data-topicid="8855" href="/d/drug information/8855.html" rel="external">decitabine</a> appears the most promising, but data are very limited [<a href="#rid16">16</a>]. A trial including combination treatment with decitabine and the pharmacokinetic enhancer tetrahydrouridine (THU) is ongoing [<a href="#rid18">18</a>]. Other epigenetic drugs including sodium dimethyl butyrate, <a class="drug drug_general" data-topicid="9491" href="/d/drug information/9491.html" rel="external">vorinostat</a>, and an inhibitor of lysine-specific demethylase (LSD-1) did not significantly elevate Hb F or were terminated early. (See  <a class="medical medical_review" href="/d/html/14601.html" rel="external">"Principles of epigenetics"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunomodulatory changes</strong> – In mouse models, the immunomodulatory agent, <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a>, led to modest increases of Hb F similar to <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, with preserved bone marrow function and enhanced erythropoiesis [<a href="#rid19">19</a>]. One phosphodiesterase-9 inhibitor (IMR-687) also increased Hb F and decreased hemolysis [<a href="#rid20">20</a>]. <a class="drug drug_general" data-topicid="8872" href="/d/drug information/8872.html" rel="external">Cilostazol</a> (OPC-13013) is a reversible <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sciencedirect.com%2Ftopics%2Fmedicine-and-dentistry%2Fpde3-inhibitor&amp;token=UPGBYwuOV7wKq98KZB3HqZRO%2BkGLo%2FD9frvr%2B7h6VQJAbOGYw%2FeSL6jDeoRQf%2F6LkUgiPxk3yWzqSn8N1QUXIUGaZmFvSbKm%2BvdB8N2YgsY%3D&amp;TOPIC_ID=110324" target="_blank">type III phosphodiesterase inhibitor</a> with <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sciencedirect.com%2Ftopics%2Fmedicine-and-dentistry%2Fantiplatelet-drug&amp;token=Le2c4RlMYbLQVHkeMqrseI8nG7u635i%2Fnd%2BDzmU4zZkjOsgdtZsFbUrQvGaOt2IyU93lZ%2BXhtdmZaWXliZH6N%2FflYNawpcTB2b7Or4uZfMY%3D&amp;TOPIC_ID=110324" target="_blank">antiplatelet and</a> vasodilating properties. In vitro, cilostazol induced red blood cell (RBC) differentiation and Hb F production [<a href="#rid21">21</a>]. In a murine model, it led to gamma globin mRNA upregulation and an increase in Hb F-producing RBCs.</p><p></p><p>Curative therapies that increase Hb F levels are also being pursued. (See <a class="local">'Gamma globin upregulation via targeting BCL11A or the gamma globin promotor'</a> below and  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p class="headingAnchor" id="H3783667238"><span class="h2">Reducing Hb S polymerization</span><span class="headingEndMark"> — </span>Normal hemoglobin remains soluble in the cytoplasm of RBCs during repeated cycles of oxygenation and deoxygenation. In contrast, Hb S polymerizes when deoxygenated, leading to precipitation and gel formation within the cell. The rate of polymerization depends on the intracellular Hb S concentration. These polymers dramatically reduce RBC deformability and cause damage to the RBC membrane.</p><p>Once polymerization occurs, polymerization-induced membrane damage leads to cellular dehydration, which in turn further increases the Hb S concentration, resulting in a cycle of worsening polymerization. This creates a population of very dense cells that are much more prone to sickling and contribute disproportionately to vaso-occlusion. (See  <a class="medical medical_review" href="/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Effects on the RBC'</a>.)</p><p>Several agents are under investigation to inhibit Hb S polymerization, through one or more of the following mechanisms [<a href="#rid22">22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increasing Hb F production – (See <a class="local">'Increasing Hb F'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activating pyruvate kinase – (See <a class="local">'Pyruvate kinase activation (mitapivat, etavopivat)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Directly interfering with polymerization – (See <a class="local">'Increasing O2 affinity of Hb S'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improving cellular hydration – (See <a class="local">'Increasing RBC hydration (senicapoc, memantine)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improving oxygen delivery to RBCs – (See <a class="local">'Increasing oxygen delivery'</a> below.)</p><p></p><p>Voxelotor is a US Food and Drug Administration (FDA)-approved agent that directly inhibits Hb S polymerization. (See <a class="local">'FDA-approved agents'</a> above.)</p><p class="headingAnchor" id="H2500919495"><span class="h3">Pyruvate kinase activation (mitapivat, etavopivat)</span><span class="headingEndMark"> — </span>The pathophysiology of SCD involves sickle hemoglobin polymerization upon deoxygenation. (See <a class="local">'Reducing Hb S polymerization'</a> above.)</p><p>RBCs with sickle hemoglobin are prone to deoxygenation; they have decreased oxygen affinity due to increased 2,3-diphosphoglycerate (2,3-DPG). (See  <a class="medical medical_review" href="/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Effects on the RBC'</a>.)</p><p>Thus, increasing oxygen affinity by manipulating 2,3-DPG levels might reduce Hb S polymerization. This is feasible because 2,3-DPG levels are controlled by the RBC enzyme pyruvate kinase (PK), and small molecule activators of PK are under study. (See  <a class="medical medical_review" href="/d/html/7129.html" rel="external">"Pyruvate kinase deficiency", section on 'PK enzymatic function'</a>.)</p><p>Two agents that increase PK activity and decrease 2,3-DPG levels are under study:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="135030" href="/d/drug information/135030.html" rel="external">Mitapivat</a> (MAG-348)</p><p class="bulletIndent1"><span class="glyph">●</span>Etavopivat (FT-4202)</p><p></p><p>A phase 1 dose-escalation study of <a class="drug drug_general" data-topicid="135030" href="/d/drug information/135030.html" rel="external">mitapivat</a> in 16 patients reported that at the 50 mg twice daily dose level, mean hemoglobin increased by 1.2 g/dL compared with baseline [<a href="#rid23">23</a>]. There were dose-dependent increases in ATP and decreases in 2,3-DPG levels and improvements in hemolysis markers, with a tolerable safety profile. These results were confirmed in a study involving an additional nine patients [<a href="#rid24">24</a>].</p><p><a class="drug drug_general" data-topicid="135030" href="/d/drug information/135030.html" rel="external">Mitapivat</a> can also be used to treat PK deficiency because it can increase the activity of dysfunctional variants of PK. (See  <a class="medical medical_review" href="/d/html/7129.html" rel="external">"Pyruvate kinase deficiency", section on 'Treatment'</a>.)</p><p>Etavopivat has shown promise in decreasing 2,3-DPG levels and increasing oxygen affinity in nonhuman primates and healthy volunteers [<a href="#rid25">25,26</a>]. RBCs collected from patients treated with etavopivat displayed increased Hb-oxygen affinity and reduced sickling under deoxygenation. Clinical trials are ongoing.</p><p class="headingAnchor" id="H3000141822"><span class="h3">Increasing O2 affinity of Hb S</span><span class="headingEndMark"> — </span>A small molecule that binds noncovalently to Hb S and increases its oxygen affinity was identified using an in-silico screening strategy [<a href="#rid27">27</a>]. In a mouse model, this compound decreased sickling and increased hemoglobin levels [<a href="#rid28">28</a>]. This compound is being pursued clinically, with initial testing in healthy volunteers [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H1878816785"><span class="h3">Increasing RBC hydration (senicapoc, memantine)</span><span class="headingEndMark"> — </span>Ion transport channels in the red blood cell (RBC) membrane control hemoglobin concentration by regulating the amount of intracellular solutes and free water. The RBC membrane has channels for potassium (K), sodium (Na), chloride (Cl), and other solutes, as discussed in detail separately. Increasing RBC hydration is a potential means of decreasing Hb S polymerization by decreasing its concentration in the RBC.</p><p>The Gardos channel (a calcium-activated K channel) is an attractive target for reducing Hb S concentration because Gardos channel inhibitors are already in clinical use for other indications.</p><p>Senicapoc (ICA-17043) is a highly potent Gardos channel inhibitor with good preclinical evidence of efficacy in improving RBC hydration. In a 2011 trial that randomly assigned 289 individuals with SCD to receive placebo or senicapoc, laboratory parameters improved (hemoglobin, cell hydration) but there was no reduction in pain episodes [<a href="#rid30">30</a>]. The hemoglobin response with senicapoc was similar to that with 900 mg <a class="drug drug_general" data-topicid="126260" href="/d/drug information/126260.html" rel="external">voxelotor</a>; although, larger reductions in markers of hemolysis were seen after treatment with senicapoc [<a href="#rid31">31</a>].</p><p>The Gardos channel inhibitor <a class="drug drug_general" data-topicid="9287" href="/d/drug information/9287.html" rel="external">clotrimazole</a> was previously studied in five individuals with SCD without clinical improvement [<a href="#rid32">32</a>].</p><p>N-methyl D-aspartate (NMDA) receptors are upregulated in RBCs of patients with SCD, and calcium uptake via these non-selective cation channels has a major impact on RBC hydration and Hb S polymerization. In vitro treatment of RBCs from individuals with SCD using the NMDA receptor inhibitor <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> led to RBC hydration and reduced sickling [<a href="#rid33">33</a>]. A study of the safety, tolerability, and efficacy of memantine as a long-term treatment of SCD is ongoing.</p><p class="headingAnchor" id="H2962447655"><span class="h3">Increasing oxygen delivery</span><span class="headingEndMark"> — </span>Sanguinate (pegylated bovine carboxyhemoglobin) is designed to deliver carbon monoxide as well as oxygen to tissues. Sanguinate has also been shown in vitro to deliver oxygen and carbon monoxide to sickled RBCs, reversing sickling [<a href="#rid34">34</a>]. A study involving 24 adults with homozygous SCD concluded that Sanguinate was safe [<a href="#rid35">35</a>]. A study using Sanguinate to treat vaso-occlusive pain has been completed.</p><p class="headingAnchor" id="H928935970"><span class="h3">Decreasing intracellular hemoglobin concentration</span><span class="headingEndMark"> — </span>The tendency of Hb S to polymerize is strongly dependent on the intracellular Hb S concentration; a relatively small decrease in intracellular Hb S concentration may inhibit HbS polymerization and its sequelae. (See  <a class="medical medical_review" href="/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Hb S polymerization and fiber formation'</a>.)</p><p>Vamifeport is an oral ferroportin inhibitor that restricts intracellular iron and hemoglobin within RBCs, leading to decreased markers of hemolysis in a mouse model of SCD [<a href="#rid36">36</a>]. Vascular cell adhesion molule-1 (VCAM-1), a biomarker of vascular inflammation, was also decreased, and adhesivity of vamifeport-treated blood cells to the endothelium was reduced. A clinical trial is ongoing to evaluate markers of hemolysis in patients with SCD treated with vamifeport [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H4245580052"><span class="h2">Decreasing inflammation</span></p><p class="headingAnchor" id="H2043484672"><span class="h3">Decreasing cell adhesion</span></p><p class="headingAnchor" id="H3041613815"><span class="h4">Blocking selectin binding (rivipansel)</span><span class="headingEndMark"> — </span>Selectins are cell-surface adhesion molecules expressed on endothelial cells (E-selectin), white blood cells, and platelets (P [for platelet]-selectin) that may contribute to increased adhesion between blood cells and the microvasculature that promotes vaso-occlusion. (See  <a class="medical medical_review" href="/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Adhesion of sickled cells to the vascular endothelium'</a>.)</p><p><a class="drug drug_general" data-topicid="126184" href="/d/drug information/126184.html" rel="external">Crizanlizumab</a> is a P-selectin-blocking monoclonal antibody therapy that was approved by the FDA in late 2019. (See  <a class="medical medical_review" href="/d/html/126298.html" rel="external">"Disease-modifying therapies to prevent pain and other complications of sickle cell disease", section on 'Crizanlizumab'</a>.)</p><p>Rivipansel (GMI-1070) is a small molecule pan-selectin inhibitor that is administered intravenously. In a randomized trial involving 345 participants (204 adults and 141 children) who were hospitalized for vaso-occlusive pain, rivipansel did not appreciably alter the time to discharge [<a href="#rid38">38</a>]. </p><p class="headingAnchor" id="H2098591431"><span class="h4">Antiinflammatory heparinoid (sevuparin)</span><span class="headingEndMark"> — </span>Sevuparin is a short heparinoid altered to remove its anticoagulant properties while maintaining its antiinflammatory, anti-aggregation, and anti-adhesive properties. In a trial that randomly assigned 144 adults with SCD to receive sevuparin or placebo intravenously for two to seven days, there was no significant difference between groups in the median time to resolution of vaso-occlusive pain [<a href="#rid39">39</a>]. There was no significant difference in the median time to vaso-occlusive pain resolution between the sevuparin and placebo groups (100.4 hours [95% CI 85.5-116.8]) <em>versus</em> 86.4 hours [70.6-95.1]; hazard ratio [HR] 0.89, 95% CI 0.6-1.3]). Serious adverse events occurred in 22 percent of patients in both arms. The observation that sevuparin did not attenuate recovery to baseline for acute vaso-occlusive pain events does not mean therapy will be ineffective for pain prevention, only that sevuparin therapy is not beneficial for abating a severe vaso-occlusive pain episode requiring hospitalization. Further research in this area is needed.</p><p class="headingAnchor" id="H1979724697"><span class="h4">Decreasing neutrophil interactions (IVIG)</span><span class="headingEndMark"> — </span>Neutrophil interactions with RBCs and endothelial cells could contribute to vaso-occlusion by creating a nidus of adhesion and retarded blood flow. (See  <a class="medical medical_review" href="/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Inflammation'</a>.)</p><p>Decreases in neutrophil counts may be one of mechanisms by which <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> reduces vaso-occlusion. (See  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease", section on 'Mechanism of action'</a>.)</p><p>Intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) has been studied to improve outcomes of vaso-occlusive pain. In a mouse model of SCD, IVIG decreased neutrophil adhesion to the endothelium and neutrophil interactions with RBCs [<a href="#rid40">40,41</a>]. Preliminary studies in children and adolescents with SCD suggest a trend towards shorter duration of vaso-occlusive pain with IVIG, although opioid use was not dramatically affected [<a href="#rid42">42</a>]. </p><p>Administration of recombinant TGF-β1 administration decreased TNFα-induced leukocyte rolling, extravasation, and adhesion in a murine SCD model [<a href="#rid43">43</a>]. On the other hand, inhibition of TGF-β increased those factors.</p><p class="headingAnchor" id="H3255757652"><span class="h4">Decreasing neutrophil activation and adhesion</span><span class="headingEndMark"> — </span>Abnormal neutrophils may contribute to thromboinflammation in SCD. Annexin A1 (AnxA1) enables resolution of inflammation through formyl peptide receptors (FPR). In a mouse model of SCD, administration of the AnxA1 mimetic peptide AnxA1Ac2-26 increased blood flow cessation time in cerebral venules and arterioles [<a href="#rid44">44</a>]. This effect was reversed in SCD mice that were neutropenic prior to peptide administration, suggesting the decreased flow-cessation time in SCD mice is neutrophil dependent.</p><p>The oral tyrosine kinase inhibitor <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> mesylate reduces neutrophil count and may decrease adhesion to the endothelium. In a mouse model of SCD, imatinib mesylate prevented neutrophil adhesion to inflammatory activated vascular endothelial cells [<a href="#rid45">45,46</a>]. Imatinib also decreased the hypoxia/reperfusion-induced inflammatory response in the lungs and kidneys. A trial is ongoing to evaluate whether imatinib decreases the frequency of vaso-occlusive pain in adults with SCD [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H2569536469"><span class="h4">Decreasing sickle RBC-endothelial adhesion</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="143378" href="/d/drug information/143378.html" rel="external">Recombinant ADAMTS13</a> – Ultralarge von Willebrand factor (ULVWF) multimers promote sickle RBC-endothelial adhesion. The metalloprotease ADAMTS13 cleaves ULVWF multimers. In one study, the ratio of ADAMTS13 to VWF:Ag was decreased in individuals with SCD, especially during a pain episode [<a href="#rid48">48</a>]. In a murine model of SCD vaso-occlusion, administration of recombinant ADAMTS13 reduced hemolysis and inflammation in the lungs and kidneys [<a href="#rid49">49</a>]. A clinical trial is ongoing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Olinciguat</strong> – Olinciguat is a soluble guanylyl cyclase. In a mouse model of SCD, olinciguat improved survival and biomarkers of leukocyte-endothelial cell interactions and endothelial cell activation following treatment with tumor necrosis factor (TNF)-alpha [<a href="#rid50">50</a>]. A clinical trial is ongoing.</p><p></p><p class="headingAnchor" id="H3950245607"><span class="h4">Decreasing inflammasome activation (canakinumab)</span><span class="headingEndMark"> — </span>Inflammasomes are cytosolic multiprotein oligomers of the innate immune system that promote inflammation. Activation of inflammasomes leads to an inflammatory cascade that includes cleavage of pro-interleukin-1 beta (pro-IL-1b) into its active form, IL-1b, thereby inducing other inflammatory responses.</p><p><a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">Canakinumab</a> is a monoclonal antibody that inhibits IL-1b. In a randomized trial involving 49 individuals with SCD ages 8 to 20 years who had two or more vaso-occlusive events in the previous year, treatment with canakinumab for 24 weeks led to a modest decrease in the number of hospitalizations (mean, 0.9 versus 1.1 per patient), a shorter average duration of hospitalization (mean 6 versus 16; maximum 37 versus 127), and fewer days of opioid use (27 versus 48 days) [<a href="#rid51">51</a>]. Clinically meaningful pain reductions recorded by electronic diary were not statistically different in the canakinumab group compared with the placebo group. Markers of inflammation including high-sensitivity C-reactive protein, total leukocyte count, and neutrophils showed greater reductions in the canakinumab group. Therapy was well tolerated without an increase in infectious complications.</p><p class="headingAnchor" id="H1324001860"><span class="h4">Decreasing platelet binding</span><span class="headingEndMark"> — </span>Platelet activation is increased at baseline in SCD, and it is further increased during vaso-occlusive events, leading to the hypothesis that blocking platelet function might decrease vaso-occlusion. However, two randomized trials failed to show a benefit. A 2022 trial comparing the platelet adenosine diphosphate (ADP) P2Y<sub>12</sub> inhibitor <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> versus placebo in children with SCD did not show a statistically significant reduction in pain episodes or other endpoints (annualized rate of vaso-occlusive pain episodes, 2.74 with ticagrelor and 2.60 with placebo; rate ratio 1.06, 95% CI 0.75-1.50) [<a href="#rid52">52</a>]. The 2016 DOVE trial evaluating the ADP P2Y<sub>12</sub> inhibitor <a class="drug drug_general" data-topicid="9533" href="/d/drug information/9533.html" rel="external">prasugrel</a> also did not show a meaningful reduction in vaso-occlusive episodes [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H275835584"><span class="h3">Decreasing oxidative stress (cathepsin B inhibitor, arginine)</span><span class="headingEndMark"> — </span>Oxidative stress might contribute to vaso-occlusion by affecting the vasculature (vascular tone or adhesivity). (See  <a class="medical medical_review" href="/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Vasoconstriction'</a> and  <a class="medical medical_review" href="/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Hypercoagulable state'</a>.)</p><p>Oral L-glutamine is an FDA-approved agent for SCD that likely reduces oxidative stress by increasing the relative amount of reduced nicotinamide adenine dinucleotides in sickle RBCs [<a href="#rid54">54</a>]. L-glutamine decreases the frequency of hospitalizations for vaso-occlusive pain, even in individuals taking <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>. (See  <a class="medical medical_review" href="/d/html/126298.html" rel="external">"Disease-modifying therapies to prevent pain and other complications of sickle cell disease"</a>.)</p><p>Other agents that might reduce oxidative stress are under investigation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhibitor of cathepsin B</strong> – Investigators have reported abnormal retention of mitochondria in the RBCs of some individuals with SCD and in a mouse model [<a href="#rid55">55,56</a>]. Autophagy dysregulation may be responsible for the abnormal mitochondrial retention. Cathepsin B, a negative regulator of autophagy, was found to be overexpressed in the reticulocytes of patients with SCD and in the mouse model, and unpublished reports suggest that the cathepsin B inhibitor E64d might be a therapeutic target.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>L-arginine</strong> – L-arginine is an amino acid that is the obligate substrate for nitric oxide production; levels of arginine and nitric oxide are depleted by hemolysis in SCD [<a href="#rid57">57,58</a>]. Low bioavailability of arginine is associated with adverse clinical outcomes in SCD, including increased risk of pulmonary hypertension, pain severity, and early mortality [<a href="#rid59">59-63</a>]. Studies have demonstrated that arginine increases nitric oxide levels and lowers oxidative stress in children with SCD [<a href="#rid64">64-66</a>].</p><p></p><p class="bulletIndent1">Arginine is also an endogenous analgesic with opioid-sparing effects [<a href="#rid67">67-70</a>]. In randomized trials in children with SCD-associated vaso-occlusive pain, arginine decreased pain scores relative to placebo and improved cardiopulmonary parameters including tricuspid regurgitant jet velocity and systolic blood pressure [<a href="#rid67">67-73</a>]. Further demonstrations of marked analgesia were reported in non-SCD patients with various forms of pain approximately 30 to 40 minutes after treatment with intravenous arginine, with a dose-dependent effect that lasted 6 to 24 hours and was blocked by intravenous <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> [<a href="#rid69">69,70</a>].</p><p></p><p class="headingAnchor" id="H3347957784"><span class="h2">Decreasing hemolysis (hemopexin)</span><span class="headingEndMark"> — </span>Hemolyzed sickle RBCs release heme, which induces expression of pro-inflammatory adhesion molecules and cytokines by endothelium and blood cells, promoting vaso-occlusion.</p><p></p><p>Hemopexin scavenges heme in plasma. In a murine model of SCD, injection of free hemoglobin induced vaso-occlusion [<a href="#rid74">74</a>]. Hemopexin administration prevented or decreased hemoglobin-induced and hypoxia/reoxygenation-induced vaso-occlusion in a dose-dependent manner. Hemopexin was given safely to rats and nonhuman primates. A clinical trial is ongoing.</p><p class="headingAnchor" id="H1986656560"><span class="h2">Decreasing pain (topical capsaicin, arginine)</span><span class="headingEndMark"> — </span>TRPV1 (transient receptor potential cation channel, subfamily V, member 1, also a vanilloid and <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">capsaicin</a> receptor) is a nociceptive ion channel found to be upregulated in a mouse model of SCD; it may have a role in the transition from acute vaso-occlusive pain to peripheral sensitization and eventually central sensitization [<a href="#rid75">75</a>]. In a study involving 10 patients with SCD treated with 8 percent topical capsaicin, pain scores improved significantly without severe adverse events [<a href="#rid76">76</a>].</p><p>L-arginine also has natural analgesic effects. (See <a class="local">'Decreasing oxidative stress (cathepsin B inhibitor, arginine)'</a> above.)</p><p class="headingAnchor" id="H1510560494"><span class="h1">THERAPIES WITH CURATIVE INTENT</span></p><p class="headingAnchor" id="H218958353"><span class="h2">Overview of curative therapies</span><span class="headingEndMark"> — </span>Traditional allogeneic hematopoietic stem cell transplantation (HSCT), modifications of allogeneic transplantation (alternative donor, haploidentical donor), and autologous transplantation using hematopoietic stem cells modified by gene therapy or gene editing are the only potentially curative treatments for SCD; none of the pharmacologic agents that can be offered to individuals with SCD offers a cure. </p><p>We consider all curative therapies for SCD to be investigational, although others may consider this view to be conservative [<a href="#rid77">77</a>]. (See <a class="local">'When to consider investigational therapies'</a> above.)</p><p>The following considerations apply:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Informed consent</strong> – The potential benefit of curative therapies must be carefully balanced with the risks of life-threatening complications and other morbidities of HSCT. Individuals with SCD should have the opportunity to understand what investigational therapies are available (pharmacologic and curative) and their risks and benefits. (See <a class="local">'When to consider investigational therapies'</a> above.)</p><p></p><p class="bulletIndent1">Some transplant centers perform transplantation in individuals with SCD outside of a clinical trial. However, we consider all forms of transplantation in SCD to be investigational because the optimal approach has not been determined. This includes the stem cell source (bone marrow, peripheral blood, or cord blood), the donor (matched related, haploidentical related, matched unrelated, or modified autologous hematopoietic stem cells [HSCs]), the conditioning regimen (myeloablative or nonmyeloablative), and post-transplant care. The approach that maximizes benefit and minimizes short-, medium-, and long-term adverse health effects is unknown. Patients with SCD should have the opportunity to discuss risks and benefits of transplantation with their primary hematologist as well as experts at a center that performs transplant and clinical trials of pharmacologic therapy to better understand whether to pursue an evaluation.</p><p></p><p class="bulletIndent1">The evaluation does not necessarily imply that transplantation is indicated. It is a consultation and an opportunity to understand the procedure, expected outcomes, and in some cases, to determine whether a sibling is a potential donor or whether there are other donor options (including modified autologous HSCs) that can be pursued.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Appropriateness</strong> – We are most likely to consider curative therapy in children and adults with complications of SCD associated with early mortality or severe morbidity. This includes the following complications not responsive to standard therapies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Strokes [<a href="#rid78">78</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Life-threatening acute chest syndrome</p><p class="bulletIndent2"><span class="glyph">•</span>Progressive heart disease [<a href="#rid79">79,80</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Progressive lung disease [<a href="#rid81">81</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Progressive kidney disease [<a href="#rid82">82-85</a>] </p><p class="bulletIndent2"><span class="glyph">•</span>Life-limiting pain</p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent priapism</p><p></p><p class="bulletIndent1">Patient and family values and preferences carry significant weight in these decisions due to the investigational nature of curative therapies and the high up-front risks. (See <a class="local">'Candidates for allogeneic transplantation'</a> below and <a class="local">'Gene therapy and gene editing'</a> below and  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oversight</strong> – Clinical trials evaluating curative therapy should only be pursued if they have appropriate strong research governance oversight (typically including registration on <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=110324" target="_blank">clinicaltrials.gov</a>). This includes institutional review board (IRB) review and involvement of a data safety monitoring board (DSMB) to ensure appropriate stopping rules for excess deaths, graft failure, or severe chronic graft-versus-host disease (GVHD).</p><p></p><p class="bulletIndent1">In children, the IRB and DSMB must adhere to the code of federal regulation (CFR) requirement for research greater than minimum risk (45 CFR § 46.405[b]), which states that the relationship between anticipated benefit and risk must be at least as favorable as available alternative approaches [<a href="#rid86">86</a>]. In children in the United States and Europe, survival to age 18 with standard therapy is 99 percent; thus, investigational curative therapies must be at least as good as standard therapy or attenuate progressive effects on the brain, heart, lung, or kidney. This CFR requirement does not apply to adults, and most adults will meet broad clinical trial entry criteria for curative therapy trials.</p><p></p><p class="bulletIndent1">Given the shortened life-span of adults with SCD, we are in favor of adults being informed of all clinical trial options for curative therapy that have an appropriate DSMB and with stopping rules in place [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease", section on 'Survival and prognosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach</strong> – The most well-established form of curative therapy is matched related donor HSCT using myeloablative conditioning. This approach has the longest follow-up period. However, myeloablative therapy is associated with intermediate- and long-term sequelae that have not been rigorously studied and may be too toxic for adults. Due to these limitations, non-myeloablative matched related donor transplant has been developed primarily for adults with SCD, with significant success, although experience is somewhat limited. (See <a class="local">'Allogeneic HSC transplantation (matched related or alternative donor)'</a> below and  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1">Expansion of the non-myeloablative matched related donor transplant protocol to children is ongoing as part of a clinical trial.</p><p></p><p>Ensuring that clinical trials meet these criteria is a time-consuming process, and resources to assist in reviewing clinical trials (eg, on <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=110324" target="_blank">clinicaltrials.gov</a>) are limited. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=110324" target="_blank">clinicaltrials.gov</a> website allows filtering on various trial attributes (age group, recruiting); nevertheless, the number of available trials can be large and in flux. Perhaps the best way to ensure that all individuals interested in pursuing these therapies can reasonably weigh their options is to refer to a center where experts in SCD and in HSCT can each provide consultation and guidance.</p><p>There are few premier transplant centers that are developing novel curative therapies based on preclinical models, and we advise our patients, especially children, to seek out these resources rather than enrolling in small, single-center trials that cannot provide this level of informed consent and research oversight. The referral often will be to a different center from the one where the patient receives their primary SCD care; this has the advantage of providing additional guidance to the patient and family without the risk of bias introduced by self-referral.</p><p>Regardless of the type of HSCT, few studies have documented the intermediate and long-term health effects of curative therapy. Late effects studies for patients with SCD are needed to evaluate the impact of the various types of curative therapy on organs that are associated with a high risk of early morbidity and mortality, including hematologic malignancy, particularly acute myeloid leukemia/myelodysplastic syndrome (AML/MDS), heart, lung, kidney, and brain, as well as how curative therapy impacts pain, fertility, and quality of life [<a href="#rid87">87,88</a>].</p><p>Further studies are indicated to evaluate established and unforeseen sequelae of conditioning regimens required for curative therapy for SCD. Multi-center long-term health effects studies for SCD are underway. (See  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease", section on 'Clinical experience/transplant outcomes'</a>.)</p><p class="headingAnchor" id="H200606513"><span class="h2">Allogeneic HSC transplantation (matched related or alternative donor)</span><span class="headingEndMark"> — </span>Allogeneic hematopoietic stem cell (HSC) transplantation is potentially curative for SCD because it replaces the individual's HSCs with HSCs that carry normal beta globin genes or that are heterozygous for the sickle cell variant (from a donor with sickle cell trait). (See  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p class="headingAnchor" id="H2574541699"><span class="h3">Candidates for allogeneic transplantation</span><span class="headingEndMark"> — </span>Allogeneic transplantation is available to individuals who have a suitable donor and for whom the potential benefits outweigh the risks of serious transplant-related morbidity and mortality. Encouraging results are emerging for human leukocyte antigen (HLA)-matched sibling transplantation in children, using either myeloablative conditioning (high-dose chemotherapy to eliminate the patient's bone marrow and allow it to be replaced with donor hematopoietic cells) or non-myeloablative conditioning (immunoablative therapy to decrease the incidence of graft rejection and graft-versus-host disease [GVHD]) [<a href="#rid89">89-91</a>]. However, the vast majority of patients with SCD do not have HLA-matched sibling donors.</p><p>For individuals who lack an HLA-matched related donor, another option is an alternative donor such as umbilical cord blood, a matched unrelated donor, or a haploidentical donor (including a parent, child, or sibling). Many experts consider transplantation to be an investigational therapy that should only be performed in the context of a clinical trial [<a href="#rid92">92</a>]. This is mainly due to the major and life-threatening toxicities including acute and chronic GVHD and immunosuppression needed to prevent GVHD. However, emerging data regarding haploidentical transplantation may shift these views. (See  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease", section on 'Haploidentical related donor'</a>.)</p><p>Many physicians taking care of patients with SCD have adopted a wait-and-see approach because of the variability in the clinical course of SCD, the uncertainty in identifying patients who are most likely to have severe disease complications, the risks associated with the procedure, and the possibility that investigational therapies with fewer toxicities may become available in the reasonably near future. Decisions should be made based on response to pharmacologic therapy, perceived benefits and risks to the individual patient, access to clinical trials, and proper education of the patient and family, ideally by a transplant team for those individuals considered to have more severe disease.</p><p>Donor selection, conditioning regimens, alternative donors, and outcomes from clinical studies are presented separately. (See  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p class="headingAnchor" id="H712001480"><span class="h3">Concern about myeloid malignancy in allogeneic transplantation</span><span class="headingEndMark"> — </span>Myeloid malignancies have been reported following allogeneic HSCT, particularly in adults when therapy was used to produce mixed donor chimerism as opposed to full donor chimerism and following graft rejection [<a href="#rid93">93</a>]. Studies using these platforms have reported 5 of 120 individuals (approximately 4 percent) developed MDS or AML after haploidentical or HLA-matched sibling HSCT for SCD [<a href="#rid94">94,95</a>]. On the other hand, in a subsequent report in 900 SCD HSCT recipients, most of whom were children who received HLA-matched related donor HSCT with a myeloablative conditioning regimen with the goal of full donor chimerism, the rate of MDS/AML was &lt;0.5 percent [<a href="#rid96">96</a>]. The pathogenesis of myeloid malignancy development following HSCT or HSCT with gene therapy/gene editing in individuals is unknown and warrants further investigation. (See <a class="local">'Concern about myeloid malignancy in gene therapy studies'</a> below and  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p class="headingAnchor" id="H1521590660"><span class="h2">Gene therapy and gene editing</span><span class="headingEndMark"> — </span>Gene therapy (introducing a new gene) and gene editing (altering the sequence of an endogenous gene) have the potential to cure SCD [<a href="#rid97">97,98</a>]. Unlike allogeneic transplantation, these approaches modify the person's own HSCs, and concerns about GVHD do not apply. Typically, the endogenous HSCs are harvested, manipulations are done in the laboratory, and the cells are reinfused as part of an autologous transplant. CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9 is one of the most studied tools for gene editing. (See  <a class="medical medical_review" href="/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Gene editing'</a>.)</p><p>In December of 2023, the US Food and Drug Administration (FDA) approved two autologous cell-based therapies using gene therapy (<a class="drug drug_general" data-topicid="143658" href="/d/drug information/143658.html" rel="external">lovotibeglogene autotemcel</a> [lovo-cel, Lyfgenia]) and gene editing (<a class="drug drug_general" data-topicid="143657" href="/d/drug information/143657.html" rel="external">exagamglogene autotemcel</a> [exa-cel, Casgevy]) [<a href="#rid99">99-101</a>].</p><p>Several approaches are under investigation, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Replacing the abnormal allele at the beta globin gene locus (<em>HBB</em><em><sup>S</sup></em>) with the wild-type <em>HBB</em><em><sup>A</sup></em> allele or providing a corrected beta globin gene.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing a modified beta globin gene that has "corrective" properties. For lovo-cel, autologous CD34-enriched cells are treated with a lentivirus encoding a beta globin transgene that has been modified to express the T87Q variant, which is thought to block sickle hemoglobin polymerization. (See <a class="local">'Anti-sickling beta globin gene'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Altering the normal hemoglobin switching program to revert to the fetal program, which uses the gamma globin gene to make fetal hemoglobin (Hb F) instead of the beta globin gene, which makes adult hemoglobin (Hb A). For exa-cel, autologous CD34-enriched cells are treated with CRISPR-Cas9 to disrupt the <em>BCL11A</em> gene, leading to increased gamma globin expression and increased Hb F levels. (See <a class="local">'Gamma globin upregulation via targeting BCL11A or the gamma globin promotor'</a> below.)</p><p></p><p>In vitro studies and animal models have provided evidence for the feasibility of these approaches [<a href="#rid102">102-107</a>]. However, issues remain related to the safety and efficacy of the delivery viruses (or other delivery methods).</p><p>Other areas of active research include whether alternatives to myeloablative therapy can be used to prepare the individual for infusion of the autologous HSCs, or whether the gene therapy or gene editing construct can be delivered directly to the patient rather than to their HSCs in the laboratory [<a href="#rid108">108</a>]. (See  <a class="medical medical_review" href="/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'In vitro versus in vivo transduction'</a>.)</p><p>As with other autosomal recessive conditions, it is not necessary to completely eliminate expression of the disease gene. Based on a model developed in the allogeneic setting, correction of approximately 20 percent of HSCs appears sufficient to reverse the sickle phenotype due to vast differences in red blood cell (RBC) survival between healthy RBCs and sickle RBCs [<a href="#rid109">109</a>].</p><p class="headingAnchor" id="H1695887754"><span class="h3">Beta globin gene correction</span><span class="headingEndMark"> — </span>The sickle cell variant is a single point mutation, and reversion to the wild-type sequence at one or both alleles of the <em>HBB</em> locus could convert SCD to sickle cell trait, a benign carrier condition, or to normal adult hemoglobin (Hb A).</p><p>Gene correction (which takes advantage of homology-directed repair) and gene editing are processes by which a wild-type beta globin gene is used as a template for endonucleases to "repair" the mutant sequence (see  <a class="medical medical_review" href="/d/html/2898.html" rel="external">"Genetics: Glossary of terms", section on 'Gene editing'</a>). A preclinical model using this approach was able to correct the sickle mutation in cultured bone marrow cells from patients with SCD, and cells manipulated in this manner could differentiate and restore hematopoiesis in a mouse model [<a href="#rid110">110</a>].</p><p>Nulabeglogene autogedtemcel (nula-cel, formerly GPH101) is a CRISPR-Cas9 gene editing system used to correct the sickle cell mutation. In January 2023, a clinical trial was voluntarily paused due to unexpected cytopenias that were attributed to the therapy [<a href="#rid111">111,112</a>].</p><p class="headingAnchor" id="H3499757082"><span class="h3">Anti-sickling beta globin gene</span><span class="headingEndMark"> — </span>An artificial version of the beta globin gene has been developed that creates an amino acid substitution of glutamine for threonine at position 87 (beta globin T87Q) [<a href="#rid102">102</a>]. This amino acid switch replicates the region of the gamma globin sequence that is thought to block polymerization of sickle hemoglobin in the RBC.</p><p>Gene therapy with <a class="drug drug_general" data-topicid="143658" href="/d/drug information/143658.html" rel="external">lovotibeglogene autotemcel</a> (lovotibeglogene autotemcel [lovo-cel, Lyfgenia]) consists of autologous CD34-enriched HSCs and hematopoietic progenitor cells transduced with the lentiviral vector BB305 that expresses Hb A<sup>T87Q</sup>. Clinical experience includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 2017 case report, a 13-year-old boy with SCD who had multiple vaso-occlusive pain episodes and other SCD complications that were not improved with <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> or chronic transfusions was treated with an autologous HSCT in which his own hematopoietic stem cells (HSCs) were transduced with this construct and returned to him after myeloablative chemotherapy [<a href="#rid113">113</a>]. Following engraftment, he had increasing expression of the variant until it reached stable levels of approximately 50 percent of total hemoglobin at nine months, with a reciprocal decline in Hb S expression. He required no further analgesics, and had no vaso-occlusive events during the post-transplant observation period of more than 15 months. There were no major adverse events other than the expected cytotoxicity of the conditioning regimen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2021 report describing outcomes in 35 individuals who underwent autologous HSCT using this therapy with plerixafor-mobilized peripheral blood stem cells and myeloablative conditioning, all 35 had engraftment, with a median follow-up of 17.3 months (range, 3.7 to 37.6) [<a href="#rid114">114</a>]. The following post-transplant outcomes were reported:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vaso-occlusive events decreased from a mean of 3.5 per year to a mean of 0.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Median hemoglobin increased from 8.5 g/dL to ≥11 g/dL.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hb A<sup>T87Q </sup>accounted for ≥40 percent of hemoglobin and was present in 85 percent of RBCs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hb S decreased to approximately 50 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two patients developed anemia of unknown cause, without evidence of MDS.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There was one death, 20 months after transplant, in an individual with pulmonary hypertension, left ventricular hypertrophy, and cardiac interstitial fibrosis.</p><p></p><p class="headingAnchor" id="H3287446967"><span class="h3">Gamma globin upregulation via targeting <i>BCL11A</i> or the gamma globin promotor</span><span class="headingEndMark"> — </span>The gamma globin gene is the source of gamma chains (beta-like chains) for fetal hemoglobin (Hb F), the predominant hemoglobin expressed in late gestation and early infancy. It is a separate gene from beta globin and thus does not contain the sickle mutation  (<a class="graphic graphic_figure graphicRef65642" href="/d/graphic/65642.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins", section on 'Fetal hemoglobin'</a>.)</p><p>The switch from gamma globin to beta globin expression leads to a reduction in Hb F and an increase in Hb A in early infancy. This switch is controlled in large part by the <em>BCL11A</em> gene, which encodes a transcriptional repressor of gamma globin expression. (See  <a class="medical medical_review" href="/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'BCL11A'</a>.)</p><p>Manipulations that block the function of <em>BCL11A</em> reverse the switch and can dramatically increase the levels of Hb F, which in turn can lead to a major reduction in sickling and vaso-occlusive complications. Genetic manipulations have the potential to raise Hb F levels (and decrease Hb S) to a much greater extent than <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>. </p><p>Several studies have validated the approach of targeting <em>BCL11A </em>using RNA interference (RNAi) or gene editing:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>RNAi</strong> – A study used RNAi from a lentiviral vector encoding a short hairpin RNA (shRNA) targeting <em>BCL11A </em>mRNA in individuals [<a href="#rid115">115,116</a>]. The shRNA was embedded in a microRNA to promote erythroid-specific knockdown in autologous HSCs followed by autologous HSCT. Autologous HSCT used HSCs transfected with this construct. Gene therapy was ineffective in one individual; in the remaining patients, Hb F was increased from 21 to 42 percent. Five patients with &gt;6 months of follow-up had a median of 6 (3 to 13) vaso-occlusive events prior to gene therapy and a median of 1 (0 to 1) vaso-occlusive events following gene therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gene editing using CRISPR-Cas9</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A study in two individuals (one with SCD and one with beta thalassemia) used the CRISPR-Cas9 system to disrupt<em> BCL11A </em>expression in autologous HSCs (<a class="drug drug_general" data-topicid="143657" href="/d/drug information/143657.html" rel="external">exagamglogene autotemcel</a> [exa-cel, Casgevy]) followed by autologous transplantation [<a href="#rid117">117</a>]. During approximately two years of follow-up, both individuals had dramatic increases in Hb F (43 percent in the individual with SCD and &gt;99 percent in the individual with thalassemia) and both experienced major reductions in their disease severity (no vaso-occlusive episodes and no need for transfusions). In an update involving 31 patients with SCD followed for 2 to 32 months, all were free of vaso-occlusive episodes, the mean Hb F was &gt;20 percent, and the mean total Hb was &gt;11 g/dL [<a href="#rid118">118</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>OTQ923 is a CRISPR-Cas9-based system for disrupting the gamma globin promotor region (HBG1/HBG2). In a mouse model, targeting this region led to induction of Hb F [<a href="#rid119">119</a>]. Follow-up of the first three patients with SCD treated with OTQ923 (using myeloablative <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a> conditioning and autologous HSCs treated with OTQ923) demonstrated clinical improvements (substantial reduction in vaso-occlusive episodes, discontinuation of transfusions) as well as marked increases in Hb (range, 10 to 12 g/dL), Hb F (range, 19 to 27 percent), and F cells (range, 70 to 88 percent) [<a href="#rid120">120,121</a>]. (See  <a class="medical medical_review" href="/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'Gamma globin genes (HBG2 and HBG1)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gene editing using zinc finger nucleases </strong>– Zinc finger nucleases (ZFN) are also used for gene editing. (See  <a class="medical medical_review" href="/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Gene editing'</a>.)</p><p></p><p class="bulletIndent1">BIVV003 uses ZFN to target BCL11A. In a study of four patients with SCD treated with BIVV003, Hb F increased to 12 to 41 percent, and three had complete resolution of vaso-occlusive events [<a href="#rid122">122</a>]. </p><p></p><p>Although these studies documented efficacy, there were transplant-related complications attributable to the myeloablative conditioning regimen. Additional studies using gene therapy or gene editing in SCD are under review (a fluid situation due to ongoing evaluations of patients initially treated in the early trials).</p><p>Details of Hb F regulation, RNA interference, and gene editing techniques are discussed separately [<a href="#rid123">123</a>]. (See  <a class="medical medical_review" href="/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'RNA interference'</a> and  <a class="medical medical_review" href="/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Gene editing'</a> and  <a class="medical medical_review" href="/d/html/90749.html" rel="external">"Fetal hemoglobin (Hb F) in health and disease", section on 'Hemoglobin switching and downregulation of Hb F expression'</a>.)</p><p class="headingAnchor" id="H1347444550"><span class="h3">Delta globin gene</span><span class="headingEndMark"> — </span>The delta globin gene is the source of beta globin-like chains for Hb A2, a minor adult hemoglobin that typically accounts for only 2 to 3 percent of total hemoglobin in children and adults. It is a separate gene from beta globin and thus does not contain the sickle mutation. Like Hb F, Hb A2 inhibits the polymerization of Hb S [<a href="#rid124">124,125</a>]. (See  <a class="medical medical_review" href="/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins", section on 'Hb A2'</a>.)</p><p>Studies in transgenic SCD mice highlight the possible value of increasing delta globin gene expression [<a href="#rid126">126,127</a>].</p><p>Preclinical models using gene therapy to introduce the delta globin gene have not been reported, but patients with SCD who have especially high Hb A2<sub> </sub>levels appear to have a milder clinical phenotype, suggesting that approaches to increase delta globin expression might be worthwhile [<a href="#rid124">124</a>].</p><p class="headingAnchor" id="H3925897240"><span class="h3">Concern about myeloid malignancy in gene therapy studies</span><span class="headingEndMark"> — </span>In early 2021, gene therapy studies using lentiviral vectors were suspended temporarily after 2 of 47 individuals with SCD who were participating in a study using the BB305 lentiviral vector subsequently developed myeloid malignancies (myelodysplastic syndrome [MDS] that later transformed to acute myeloid leukemia [AML] in one participant, AML in another participant) [<a href="#rid128">128</a>]. For the first participant, the investigative team concluded that MDS/AML was not related to the viral vector but was a result of the conditioning regimen [<a href="#rid129">129</a>]. Evaluation of the second patient, who had very limited engraftment of the modified HSCs and developed AML more than five years later, also determined that the gene therapy construct was unlikely to be responsible [<a href="#rid130">130</a>]. The insertion site was in a gene not known to be associated with oncogenesis and was present in most patients with SCD who received the same construct and did not develop AML, and several somatic mutations were present in the leukemic blasts unrelated to the vector but commonly seen in monosomy 7, which is known to complicate alkylating agent therapy. Low transgene expression, insufficient therapeutic response, and persistent hematopoietic stress may have contributed to somatic mutation evolution. Two other patients who were originally suspected of having MDS had transfusion-dependent anemia and trisomy 8, but there was no evidence of dysplasia or blasts on bone marrow evaluation [<a href="#rid114">114,131,132</a>].</p><p>Studies are indicated to assess for genetic risk factors for MDS and AML development after gene therapy for SCD. Hypotheses for the mechanism of leukemogenesis include insertional mutagenesis, transplant conditioning regimens, and expansion of preexisting premalignant clonal populations driven by regeneration of hematopoiesis with expansion of the autologous HSC population [<a href="#rid133">133</a>].</p><p>The optimal strategy to identify individuals with SCD who are at increased risk for transplant-related malignancy is unknown. Several strategies may be suggested but not proven to have clinical utility, such as clonal hematopoiesis screening prior to the procedure. The gene(s) and variant allele frequencies associated with an increased risk of MDS/AML following any curative therapy in SCD are unknown.</p><p>Individuals with thalassemia treated with the same lentiviral construct have not shown evidence of AML or MDS. However, no conclusive evidence exists to determine which features of disease or therapy predisposes to myeloid malignancy, from among myeloablative therapy, the lentiviral vector, SCD-related genetic predisposition, stress erythropoiesis, or some combination of these factors. MDS and AML have been observed in allogeneic transplant studies in SCD that did not involve gene therapy [<a href="#rid95">95,96,134</a>]. The cause(s) in individuals with SCD are under investigation.</p><p>Given that approximately 4 percent of participants in the gene therapy trial developed MDS/AML, coupled with the high rate of mortality, we are reluctant to advise children with severe SCD to pursue gene therapy or gene editing. While we recognize that others may have a different view, our hesitation for suggesting the relatively new gene therapy or editing trials to children is based on the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple studies have demonstrated an expected median survival of 99 percent up to 18 years of age [<a href="#rid9">9,10,80,135</a>]. (See  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease", section on 'Overall survival'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Experimental gene therapy and gene editing have not demonstrated a survival benefit equivalent to standard care.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specific to children enrolled in clinical trials, 45 code of federal regulation § 46.405(b) requires the investigational agent must be at least as safe as standard care for greater than minimal risk research [<a href="#rid11">11</a>].</p><p></p><p>As more experience is gained regarding the adverse intermediate- and long-term therapy outcomes of gene therapy and gene editing trials, a parent or guardian can make an informed decision on behalf of their child as to the risk-benefit ratio.</p><p class="headingAnchor" id="H505865029"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110843.html" rel="external">"Society guideline links: Sickle cell disease and thalassemias"</a>.)</p><p class="headingAnchor" id="H1434327661"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16730.html" rel="external">"Patient education: Sickle cell disease (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/95020.html" rel="external">"Patient education: Sickle cell trait (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/88642.html" rel="external">"Patient education: When your child has sickle cell disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2288689724"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/d/html/132604.html" rel="external">"Patient perspective: Sickle cell disease"</a>.)</p><p class="headingAnchor" id="H1132991931"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Existing therapies</strong> – <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a>, chronic transfusions, and new drugs approved by the US Food and Drug Administration (FDA) in 2017 to 2019 are effective at reducing vaso-occlusive pain and other complications of sickle cell disease (SCD). Indications are discussed in separate topic reviews. (See <a class="local">'Timeline of drug development in SCD'</a> above and  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease"</a> and  <a class="medical medical_review" href="/d/html/126298.html" rel="external">"Disease-modifying therapies to prevent pain and other complications of sickle cell disease"</a> and  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Need for new therapies</strong> – Existing therapies require lifelong administration, do not eliminate vaso-occlusive complications, and may be challenging for some individuals to take. Transfusions carry several risks and burdens and often cannot be continued indefinitely. (See <a class="local">'Limitations of available therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to consider</strong> – Pharmacologic therapies may be explored as part of a well-conducted clinical trial if vaso-occlusive complications persist despite adequately administered <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> or other disease-modifying therapies or if these therapies cannot be used. Curative therapies may be considered in individuals with progressive vaso-occlusive complications despite FDA-approved therapies. For children, we reserve matched related donor allogeneic hematopoietic stem cell (HSC) transplantation for those with preexisting stroke, silent cerebral infarcts, heart, lung, or kidney disease that is not responsive to disease-modifying therapy. For adults, we consider curative therapy if there is organ damage associated with an increased risk for early mortality, especially elevated tricuspid regurgitant velocity. (See <a class="local">'When to consider investigational therapies'</a> above and  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic approaches</strong> – Many new agents are being investigated, including drugs with the following effects (see <a class="local">'Pharmacologic therapies'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increasing fetal hemoglobin – (See <a class="local">'Increasing Hb F'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reducing sickle hemoglobin polymerization – (See <a class="local">'Reducing Hb S polymerization'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Blocking sickle RBC or neutrophil interactions with the vasculature – (See <a class="local">'Decreasing cell adhesion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreasing inflammation or oxidative stress – (See <a class="local">'Decreasing inflammation'</a> above and <a class="local">'Decreasing oxidative stress (cathepsin B inhibitor, arginine)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reducing hemolysis – (See <a class="local">'Decreasing hemolysis (hemopexin)'</a> above.)</p><p></p><p class="bulletIndent1">Combining approaches with different mechanisms might produce additive or synergistic effects. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Curative approaches </strong>– Curative approaches include allogeneic HSC transplantation using an alternative donor (haploidentical related, matched-unrelated, umbilical cord blood) or autologous transplantation using HSCs modified by gene therapy or gene editing (see <a class="local">'Therapies with curative intent'</a> above and  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>).</p><p></p><p class="bulletIndent1">Approaches to modifying autologous HSCs include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Editing the beta globin gene</p><p class="bulletIndent2"><span class="glyph">•</span>Adding an anti-sickling gene</p><p class="bulletIndent2"><span class="glyph">•</span>Upregulating gamma globin expression to increase Hb F</p><p class="bulletIndent2"><span class="glyph">•</span>Upregulating delta globin expression to increase Hb A2</p><p></p><p class="headingAnchor" id="H2531069616"><span class="h1">ACKNOWLEDGMENTS</span></p><p>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic review and was a founding Editor-in-Chief for UpToDate in Hematology.</p><p>The editorial staff at UpToDate would also like to acknowledge Griffin P Rodgers, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet 2017.</a></li><li><a class="nounderline abstract_t">Chaturvedi S, Ghafuri DL, Jordan N, et al. Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: A retrospective-prospective cohort study. Am J Hematol 2018; 93:1153.</a></li><li><a class="nounderline abstract_t">Chaube S, Murphy ML. The effects of hydroxyurea and related compounds on the rat fetus. Cancer Res 1966; 26:1448.</a></li><li><a class="nounderline abstract_t">Berthaut I, Bachir D, Kotti S, et al. Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment. Blood 2017; 130:2354.</a></li><li><a class="nounderline abstract_t">Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008; 93:988.</a></li><li><a class="nounderline abstract_t">DeBaun MR, Ghafuri DL, Rodeghier M, et al. Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis. Blood 2019; 133:615.</a></li><li><a class="nounderline abstract_t">Asare EV, Olayemi E, Boafor T, et al. Third trimester and early postpartum period of pregnancy have the greatest risk for ACS in women with SCD. Am J Hematol 2019; 94:E328.</a></li><li><a class="nounderline abstract_t">Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv 2020; 4:2656.</a></li><li><a class="nounderline abstract_t">Lê PQ, Gulbis B, Dedeken L, et al. Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment. Pediatr Blood Cancer 2015; 62:1956.</a></li><li><a class="nounderline abstract_t">Telfer P, Coen P, Chakravorty S, et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica 2007; 92:905.</a></li><li><a class="nounderline abstract_t">DeBaun MR, Clayton EW. Primum non nocere: the case against transplant for children with sickle cell anemia without progressive end-organ disease. Blood Adv 2017; 1:2568.</a></li><li><a class="nounderline abstract_t">Koshy M, Dorn L, Bressler L, et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 2000; 96:2379.</a></li><li><a class="nounderline abstract_t">DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002; 99:3905.</a></li><li><a class="nounderline abstract_t">Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003; 102:3865.</a></li><li><a class="nounderline abstract_t">Saunthararajah Y, Molokie R, Saraf S, et al. Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol 2008; 141:126.</a></li><li><a class="nounderline abstract_t">Molokie R, Lavelle D, Gowhari M, et al. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. PLoS Med 2017; 14:e1002382.</a></li><li><a class="nounderline abstract_t">Rai P, Ataga KI. Drug Therapies for the Management of Sickle Cell Disease. F1000Res 2020; 9.</a></li><li class="breakAll">Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (ASCENT1). ClinicalTrials.gov. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT05405114 (Accessed on August 16, 2023).</li><li><a class="nounderline abstract_t">Meiler SE, Wade M, Kutlar F, et al. Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood 2011; 118:1109.</a></li><li><a class="nounderline abstract_t">McArthur JG, Svenstrup N, Chen C, et al. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica 2020; 105:623.</a></li><li><a class="nounderline abstract_t">Ali H, Khan F, Musharraf SG. Cilostazol-mediated reversion of γ-globin silencing is associated with a high level of HbF production: A potential therapeutic candidate for β-globin disorders. Biomed Pharmacother 2021; 142:112058.</a></li><li><a class="nounderline abstract_t">Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood 2017; 129:2719.</a></li><li><a class="nounderline abstract_t">Xu JZ, Conrey A, Frey I, et al. A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. Blood 2022; 140:2053.</a></li><li><a class="nounderline abstract_t">van Dijk MJ, Rab MAE, van Oirschot BA, et al. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open-label study. Am J Hematol 2022; 97:E226.</a></li><li><a class="nounderline abstract_t">Schroeder P, Fulzele K, Forsyth S, et al. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. J Pharmacol Exp Ther 2022; 380:210.</a></li><li><a class="nounderline abstract_t">Forsyth S, Schroeder P, Geib J, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial. Clin Pharmacol Drug Dev 2022; 11:654.</a></li><li><a class="nounderline abstract_t">Gopalsamy A, Aulabaugh AE, Barakat A, et al. PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease. J Med Chem 2021; 64:326.</a></li><li><a class="nounderline abstract_t">Knee KM, Jasuja R, Barakat A, et al. PF-07059013: A non-covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease. Am J Hematol 2021; 96:E272.</a></li><li class="breakAll">https://clinicaltrials.gov/ct2/show/NCT04323124 (Accessed on May 19, 2021).</li><li><a class="nounderline abstract_t">Ataga KI, Reid M, Ballas SK, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol 2011; 153:92.</a></li><li><a class="nounderline abstract_t">Ataga KI, Staffa SJ, Brugnara C, Stocker JW. Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial. Br J Haematol 2021; 192:e129.</a></li><li><a class="nounderline abstract_t">Brugnara C, Gee B, Armsby CC, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996; 97:1227.</a></li><li><a class="nounderline abstract_t">Hänggi P, Makhro A, Gassmann M, et al. Red blood cells of sickle cell disease patients exhibit abnormally high abundance of N-methyl D-aspartate receptors mediating excessive calcium uptake. Br J Haematol 2014; 167:252.</a></li><li><a class="nounderline abstract_t">Abuchowski A. SANGUINATE (PEGylated Carboxyhemoglobin Bovine): Mechanism of Action and Clinical Update. Artif Organs 2017; 41:346.</a></li><li><a class="nounderline abstract_t">Misra H, Bainbridge J, Berryman J, et al. A Phase Ib open label, randomized, safety study of SANGUINATE™ in patients with sickle cell anemia. Rev Bras Hematol Hemoter 2017; 39:20.</a></li><li><a class="nounderline abstract_t">Nyffenegger N, Zennadi R, Kalleda N, et al. The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease. Blood 2022; 140:769.</a></li><li class="breakAll">Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease (ViSionSerenity). ClinicalTrials.gov. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT04817670 (Accessed on August 16, 2023).</li><li><a class="nounderline abstract_t">Dampier CD, Telen MJ, Wun T, et al. A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis. Blood 2023; 141:168.</a></li><li><a class="nounderline abstract_t">Biemond BJ, Tombak A, Kilinc Y, et al. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol 2021; 8:e334.</a></li><li><a class="nounderline abstract_t">Turhan A, Jenab P, Bruhns P, et al. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood 2004; 103:2397.</a></li><li><a class="nounderline abstract_t">Chang J, Shi PA, Chiang EY, Frenette PS. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 2008; 111:915.</a></li><li><a class="nounderline abstract_t">Manwani D, Chen G, Carullo V, et al. Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis. Am J Hematol 2015; 90:381.</a></li><li><a class="nounderline abstract_t">Torres LS, Chweih H, Fabris FCZ, et al. TGF-β1 Reduces Neutrophil Adhesion and Prevents Acute Vaso-Occlusive Processes in Sickle Cell Disease Mice. Cells 2022; 11.</a></li><li><a class="nounderline abstract_t">Ansari J, Senchenkova EY, Vital SA, et al. Targeting the AnxA1/Fpr2/ALX pathway regulates neutrophil function, promoting thromboinflammation resolution in sickle cell disease. Blood 2021; 137:1538.</a></li><li><a class="nounderline abstract_t">Federti E, Matte A, Recchiuti A, et al. In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related Injury. Hemasphere 2023; 7:e848.</a></li><li class="breakAll">IMatinib for PAin in Chronic Treatment of Sickle Cell Anemia (IMPACT SCA): A Pilot Study of Imatinib in Patients With Sickle Cell Anemia and Recurrent Vaso-occlusive Pain. Interventional (Clinical Trial). US National Library of Medicine. https://classic.clinicaltrials.gov/ct2/show/NCT03997903. (Accessed on August 10, 2023).</li><li class="breakAll">Imatinib for Pain in Sickle Cell Anemia (IMPACT). ClinicalTrials.gov. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT03997903 (Accessed on August 16, 2023).</li><li><a class="nounderline abstract_t">Schnog JJ, Kremer Hovinga JA, Krieg S, et al. ADAMTS13 activity in sickle cell disease. Am J Hematol 2006; 81:492.</a></li><li><a class="nounderline abstract_t">Rossato P, Federti E, Matte A, et al. Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease. Haematologica 2022; 107:2650.</a></li><li><a class="nounderline abstract_t">Tchernychev B, Li H, Lee SK, et al. Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease. Br J Pharmacol 2021; 178:3463.</a></li><li><a class="nounderline abstract_t">Rees DC, Kilinc Y, Unal S, et al. A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood 2022; 139:2642.</a></li><li><a class="nounderline abstract_t">Heeney MM, Abboud MR, Githanga J, et al. Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood 2022; 140:1470.</a></li><li><a class="nounderline abstract_t">Heeney MM, Hoppe CC, Abboud MR, et al. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. N Engl J Med 2016; 374:625.</a></li><li><a class="nounderline abstract_t">Niihara Y, Miller ST, Kanter J, et al. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med 2018; 379:226.</a></li><li><a class="nounderline abstract_t">Jagadeeswaran R, Vazquez BA, Thiruppathi M, et al. Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease. Exp Hematol 2017; 50:46.</a></li><li><a class="nounderline abstract_t">Tumburu L, Ghosh-Choudhary S, Seifuddin FT, et al. Circulating mitochondrial DNA is a proinflammatory DAMP in sickle cell disease. Blood 2021; 137:3116.</a></li><li><a class="nounderline abstract_t">Morris CR, Hamilton-Reeves J, Martindale RG, et al. Acquired Amino Acid Deficiencies: A Focus on Arginine and Glutamine. Nutr Clin Pract 2017; 32:30S.</a></li><li><a class="nounderline abstract_t">Gladwin MT. Revisiting the hyperhemolysis paradigm. Blood 2015; 126:695.</a></li><li><a class="nounderline abstract_t">Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005; 294:81.</a></li><li><a class="nounderline abstract_t">Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003; 168:63.</a></li><li><a class="nounderline abstract_t">Cox SE, Makani J, Komba AN, et al. Global arginine bioavailability in Tanzanian sickle cell anaemia patients at steady-state: a nested case control study of deaths versus survivors. Br J Haematol 2011; 155:522.</a></li><li><a class="nounderline abstract_t">Morris CR, Kuypers FA, Larkin S, et al. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000; 22:515.</a></li><li><a class="nounderline abstract_t">Lopez BL, Kreshak AA, Morris CR, et al. L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol 2003; 120:532.</a></li><li><a class="nounderline abstract_t">Morris CR, Vichinsky EP, van Warmerdam J, et al. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol 2003; 25:629.</a></li><li><a class="nounderline abstract_t">Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol 2000; 111:498.</a></li><li><a class="nounderline abstract_t">Morris CR, Brown LAS, Reynolds M, et al. Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain. Blood 2020; 136:1402.</a></li><li><a class="nounderline abstract_t">Morris CR, Kuypers FA, Lavrisha L, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica 2013; 98:1375.</a></li><li><a class="nounderline abstract_t">Morris CR, Bakshi N, Leake D, et al. Impact of Arginine Therapy on Clinical Outcomes, Mitochondrial Function and Oxidative Stress in Children with Sickle Cell Disease Hospitalized with Vasoocclusive Pain Episodes: A Randomized Controlled Trial. Blood 2022; 140:16.</a></li><li><a class="nounderline abstract_t">Harima A, Shimizu H, Takagi H. Analgesic effect of L-arginine in patients with persistent pain. Eur Neuropsychopharmacol 1991; 1:529.</a></li><li><a class="nounderline abstract_t">Kawabata A, Nishimura Y, Takagi H. L-leucyl-L-arginine, naltrindole and D-arginine block antinociception elicited by L-arginine in mice with carrageenin-induced hyperalgesia. Br J Pharmacol 1992; 107:1096.</a></li><li><a class="nounderline abstract_t">Onalo R, Cooper P, Cilliers A, et al. Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria. Am J Hematol 2021; 96:89.</a></li><li><a class="nounderline abstract_t">Onalo R, Cilliers A, Cooper P, Morris CR. Arginine Therapy and Cardiopulmonary Hemodynamics in Hospitalized Children with Sickle Cell Anemia: A Prospective, Double-blinded, Randomized Placebo-controlled Clinical Trial. Am J Respir Crit Care Med 2022; 206:70.</a></li><li><a class="nounderline abstract_t">Onalo R, Cilliers A, Cooper P. Impact of oral L-arginine supplementation on blood pressure dynamics in children with severe sickle cell vaso-occlusive crisis. Am J Cardiovasc Dis 2021; 11:136.</a></li><li><a class="nounderline abstract_t">Gentinetta T, Belcher JD, Brügger-Verdon V, et al. Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence. J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Hillery CA, Kerstein PC, Vilceanu D, et al. Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease. Blood 2011; 118:3376.</a></li><li><a class="nounderline abstract_t">Glaros AK, Callaghan MU, Smith WR, Zaidi AU. Targeting TRPV1 activity via high-dose capsaicin in patients with sickle cell disease. EJHaem 2022; 3:653.</a></li><li><a class="nounderline abstract_t">Fitzhugh CD, Walters MC. The case for HLA-identical sibling hematopoietic stem cell transplantation in children with symptomatic sickle cell anemia. Blood Adv 2017; 1:2563.</a></li><li><a class="nounderline abstract_t">DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv 2020; 4:1554.</a></li><li><a class="nounderline abstract_t">Maitra P, Caughey M, Robinson L, et al. Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe. Haematologica 2017; 102:626.</a></li><li><a class="nounderline abstract_t">Nouraie M, Darbari DS, Rana S, et al. Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study. Am J Hematol 2020; 95:766.</a></li><li><a class="nounderline abstract_t">Kassim AA, Payne AB, Rodeghier M, et al. Low forced expiratory volume is associated with earlier death in sickle cell anemia. Blood 2015; 126:1544.</a></li><li><a class="nounderline abstract_t">Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.</a></li><li><a class="nounderline abstract_t">McClellan AC, Luthi JC, Lynch JR, et al. High one year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol 2012; 159:360.</a></li><li><a class="nounderline abstract_t">Viner M, Zhou J, Allison D, et al. The morbidity and mortality of end stage renal disease in sickle cell disease. Am J Hematol 2019; 94:E138.</a></li><li><a class="nounderline abstract_t">Ataga KI, Zhou Q, Derebail VK, et al. Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis. Haematologica 2021; 106:1749.</a></li><li class="breakAll">https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html (Accessed on May 26, 2021).</li><li><a class="nounderline abstract_t">Fitzhugh CD, Volanakis EJ, Idassi O, et al. Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies. J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Nickel RS, Maher JY, Hsieh MH, et al. Fertility after Curative Therapy for Sickle Cell Disease: A Comprehensive Review to Guide Care. J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009; 361:2309.</a></li><li><a class="nounderline abstract_t">Alzahrani M, Damlaj M, Jeffries N, et al. Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. Br J Haematol 2021; 192:761.</a></li><li><a class="nounderline abstract_t">Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood 2017; 129:1548.</a></li><li><a class="nounderline abstract_t">Kanter J, Liem RI, Bernaudin F, et al. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. Blood Adv 2021; 5:3668.</a></li><li><a class="nounderline abstract_t">Eapen M, Brazauskas R, Williams DA, et al. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. J Clin Oncol 2023; 41:2227.</a></li><li><a class="nounderline abstract_t">Ghannam JY, Xu X, Maric I, et al. Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation. Blood 2020; 135:1185.</a></li><li><a class="nounderline abstract_t">Lawal RA, Mukherjee D, Limerick EM, et al. Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism. Blood 2022; 140:2514.</a></li><li><a class="nounderline abstract_t">Eapen M, Brazauskas R, Walters MC, et al. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol 2019; 6:e585.</a></li><li><a class="nounderline abstract_t">Mansilla-Soto J, Rivière I, Sadelain M. Genetic strategies for the treatment of sickle cell anaemia. Br J Haematol 2011; 154:715.</a></li><li><a class="nounderline abstract_t">Nienhuis AW. Development of gene therapy for blood disorders. Blood 2008; 111:4431.</a></li><li class="breakAll">FDA package insert for CASGEVY (exagamglogene autotemcel). US Food and Drug Administration. Available at: https://www.fda.gov/media/174615/download (Accessed on December 15, 2023).</li><li class="breakAll">lovotibeglogene autotemcel (Accessed on December 15, 2023).</li><li class="breakAll">FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. US Food and Drug Administration, 2023. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease (Accessed on December 15, 2023).</li><li><a class="nounderline abstract_t">Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001; 294:2368.</a></li><li><a class="nounderline abstract_t">Wu LC, Sun CW, Ryan TM, et al. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 2006; 108:1183.</a></li><li><a class="nounderline abstract_t">Perumbeti A, Higashimoto T, Urbinati F, et al. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood 2009; 114:1174.</a></li><li><a class="nounderline abstract_t">Zou J, Mali P, Huang X, et al. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011; 118:4599.</a></li><li><a class="nounderline abstract_t">Takekoshi KJ, Oh YH, Westerman KW, et al. Retroviral transfer of a human beta-globin/delta-globin hybrid gene linked to beta locus control region hypersensitive site 2 aimed at the gene therapy of sickle cell disease. Proc Natl Acad Sci U S A 1995; 92:3014.</a></li><li><a class="nounderline abstract_t">Townes TM. Gene replacement therapy for sickle cell disease and other blood disorders. Hematology Am Soc Hematol Educ Program 2008; :193.</a></li><li><a class="nounderline abstract_t">Kaiser J. Tweaking genes with CRISPR or viruses fixes blood disorders. Science 2020; 370:1254.</a></li><li><a class="nounderline abstract_t">Fitzhugh CD, Cordes S, Taylor T, et al. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood 2017; 130:1946.</a></li><li><a class="nounderline abstract_t">Hoban MD, Cost GJ, Mendel MC, et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood 2015; 125:2597.</a></li><li><a class="nounderline abstract_t">Philippidis A. Graphite Bio Pauses Lead Gene Editing Program in Sickle Cell Disease. Hum Gene Ther 2023; 34:90.</a></li><li><a class="nounderline abstract_t">Larkin HD. Sickle Cell Disease Gene Therapy Trial Paused. JAMA 2023; 329:364.</a></li><li><a class="nounderline abstract_t">Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene Therapy in a Patient with Sickle Cell Disease. N Engl J Med 2017; 376:848.</a></li><li><a class="nounderline abstract_t">Kanter J, Walters MC, Krishnamurti L, et al. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. N Engl J Med 2022; 386:617.</a></li><li><a class="nounderline abstract_t">Esrick EB, Lehmann LE, Biffi A, et al. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med 2021; 384:205.</a></li><li><a class="nounderline abstract_t">Esrick EB, Federico A, Abriss D, et al. Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial. Blood 2022; 140 (Supplement 1):10665.</a></li><li><a class="nounderline abstract_t">Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N Engl J Med 2021; 384:252.</a></li><li><a class="nounderline abstract_t">Frangoul H, Locatelli F, Bhatia M, et al. Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease. Blood 2022; 140 (Supplement 1).</a></li><li><a class="nounderline abstract_t">Métais JY, Doerfler PA, Mayuranathan T, et al. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Adv 2019; 3:3379.</a></li><li><a class="nounderline abstract_t">Sharma A, Boelens JJ, Cancio MI, et al. Treatment of Individuals with Severe Sickle Cell Disease with OTQ923, an Autologous, Ex Vivo, CRISPR/Cas9-Edited, CD34+ Hematopoietic Stem and Progenitor Cell Product, Leads to Durable Engraftment and Fetal Hemoglobin Induction. Blood 2022; 140 (Supplement 1):1906.</a></li><li><a class="nounderline abstract_t">Sharma A, Boelens JJ, Cancio M, et al. CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. N Engl J Med 2023; 389:820.</a></li><li><a class="nounderline abstract_t">Alavi A, Abedi M, Parikh S, et al. Interim Safety and Efficacy Results from a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1). Blood 2022; 140 (Supplement 1):4907.</a></li><li><a class="nounderline abstract_t">Antoniani C, Meneghini V, Lattanzi A, et al. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus. Blood 2018; 131:1960.</a></li><li><a class="nounderline abstract_t">Steinberg MH, Rodgers GP. HbA2 : biology, clinical relevance and a possible target for ameliorating sickle cell disease. Br J Haematol 2015; 170:781.</a></li><li><a class="nounderline abstract_t">Griffin PJ, Sebastiani P, Edward H, et al. The genetics of hemoglobin A2 regulation in sickle cell anemia. Am J Hematol 2014; 89:1019.</a></li><li><a class="nounderline abstract_t">Porcu S, Simbula M, Marongiu MF, et al. Delta-globin gene expression improves sickle cell disease in a humanised mouse model. Br J Haematol 2021; 193:1228.</a></li><li><a class="nounderline abstract_t">Zhu J, Li H, Aerbajinai W, et al. Kruppel-like factor 1-GATA1 fusion protein improves the sickle cell disease phenotype in mice both in vitro and in vivo. Blood 2022; 140:2276.</a></li><li class="breakAll">https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-temporary-suspension-phase-12-and-phase-3 (Accessed on February 23, 2021).</li><li><a class="nounderline abstract_t">Hsieh MM, Bonner M, Pierciey FJ, et al. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv 2020; 4:2058.</a></li><li><a class="nounderline abstract_t">Goyal S, Tisdale J, Schmidt M, et al. Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease. N Engl J Med 2022; 386:138.</a></li><li><a class="nounderline abstract_t">Philippidis A. After Analysis, Bluebird Bio Says Vector "Very Unlikely" Cause of Acute Myeloid Leukemia. Hum Gene Ther 2021; 32:332.</a></li><li><a class="nounderline abstract_t">Walters MC, Thompson AA, Kwiatkowski JL, et al. Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study. Blood 2022; 140 (Supplement 1).</a></li><li><a class="nounderline abstract_t">Jones RJ, DeBaun MR. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood 2021; 138:942.</a></li><li><a class="nounderline abstract_t">Li Y, Maule J, Neff JL, et al. Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature. Mod Pathol 2019; 32:1712.</a></li><li><a class="nounderline abstract_t">Couque N, Girard D, Ducrocq R, et al. Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines. Br J Haematol 2016; 173:927.</a></li></ol></div><div id="topicVersionRevision">Topic 110324 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28159390" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29981283" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: A retrospective-prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5911587" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The effects of hydroxyurea and related compounds on the rat fetus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972009" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18508803" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30530750" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31571271" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Third trimester and early postpartum period of pregnancy have the greatest risk for ACS in women with SCD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32559294" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26173735" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606440" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29296909" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Primum non nocere: the case against transplant for children with sickle cell anemia without progressive end-organ disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11001887" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12010787" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12907443" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18324975" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical effectiveness of decitabine in severe sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28880867" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32765834" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Drug Therapies for the Management of Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32765834" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Drug Therapies for the Management of Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536862" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31147439" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34426256" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cilostazol-mediated reversion ofγ-globin silencing is associated with a high level of HbF production: A potential therapeutic candidate forβ-globin disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28385699" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treating sickle cell disease by targeting HbS polymerization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35576529" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35384026" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35031585" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35019238" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33356244" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33891711" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : PF-07059013: A non-covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33891711" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : PF-07059013: A non-covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21323872" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33527340" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636434" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25041184" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Red blood cells of sickle cell disease patients exhibit abnormally high abundance of N-methyl D-aspartate receptors mediating excessive calcium uptake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28397407" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : SANGUINATE (PEGylated Carboxyhemoglobin Bovine): Mechanism of Action and Clinical Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28270341" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A Phase Ib open label, randomized, safety study of SANGUINATE™in patients with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35714304" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35714304" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35981565" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33894169" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14630831" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17932253" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25616042" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35406764" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : TGF-β1 Reduces Neutrophil Adhesion and Prevents Acute Vaso-Occlusive Processes in Sickle Cell Disease Mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33512489" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Targeting the AnxA1/Fpr2/ALX pathway regulates neutrophil function, promoting thromboinflammation resolution in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36874380" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36874380" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36874380" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16755558" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : ADAMTS13 activity in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35443560" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33864386" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35226723" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35849650" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26644172" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30021096" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28238805" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33661274" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Circulating mitochondrial DNA is a proinflammatory DAMP in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28388380" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Acquired Amino Acid Deficiencies: A Focus on Arginine and Glutamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26251222" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Revisiting the hyperhemolysis paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15998894" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12626350" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21595648" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Global arginine bioavailability in Tanzanian sickle cell anaemia patients at steady-state: a nested case control study of deaths versus survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11132219" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12580975" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12902916" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122090" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32384147" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23645695" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Impact of Arginine Therapy on Clinical Outcomes, Mitochondrial Function and Oxidative Stress in Children with Sickle Cell Disease Hospitalized with Vasoocclusive Pain Episodes: A Randomized Controlled Trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1822318" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Analgesic effect of L-arginine in patients with persistent pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1467831" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : L-leucyl-L-arginine, naltrindole and D-arginine block antinociception elicited by L-arginine in mice with carrageenin-induced hyperalgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33075179" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35426778" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Arginine Therapy and Cardiopulmonary Hemodynamics in Hospitalized Children with Sickle Cell Anemia: A Prospective, Double-blinded, Randomized Placebo-controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33815929" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Impact of oral L-arginine supplementation on blood pressure dynamics in children with severe sickle cell vaso-occlusive crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35160081" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Plasma-Derived Hemopexin as a Candidate Therapeutic Agent for Acute Vaso-Occlusion in Sickle Cell Disease: Preclinical Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21708890" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36051054" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Targeting TRPV1 activity via high-dose capsaicin in patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29296908" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The case for HLA-identical sibling hematopoietic stem cell transplantation in children with symptomatic sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32298430" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28104703" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243618" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26261241" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Low forced expiratory volume is associated with earlier death in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993409" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Mortality in sickle cell disease. Life expectancy and risk factors for early death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22967259" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : High one year mortality in adults with sickle cell disease and end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30773675" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The morbidity and mortality of end stage renal disease in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33179474" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33179474" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35683502" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35566443" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Fertility after Curative Therapy for Sickle Cell Disease: A Comprehensive Review to Guide Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20007560" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33534948" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27965196" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34581773" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36623245" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32062672" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36044658" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31495699" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21707580" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Genetic strategies for the treatment of sickle cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18441245" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Development of gene therapy for blood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18441245" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Development of gene therapy for blood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18441245" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Development of gene therapy for blood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18441245" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Development of gene therapy for blood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11743206" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Correction of sickle cell disease in transgenic mouse models by gene therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638928" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Correction of sickle cell disease by homologous recombination in embryonic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19474450" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21881051" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7708766" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Retroviral transfer of a human beta-globin/delta-globin hybrid gene linked to beta locus control region hypersensitive site 2 aimed at the gene therapy of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19074080" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Gene replacement therapy for sickle cell disease and other blood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33303593" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Tweaking genes with CRISPR or viruses fixes blood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28887325" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25733580" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36794977" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Graphite Bio Pauses Lead Gene Editing Program in Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36652618" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Sickle Cell Disease Gene Therapy Trial Paused.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28249145" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Gene Therapy in a Patient with Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34898139" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33283990" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33283989" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : CRISPR-Cas9 Gene Editing for Sickle Cell Disease andβ-Thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31698466" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Treatment of Individuals with Severe Sickle Cell Disease with OTQ923, an Autologous, Ex Vivo, CRISPR/Cas9-Edited, CD34+ Hematopoietic Stem and Progenitor Cell Product, Leads to Durable Engraftment and Fetal Hemoglobin Induction</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37646679" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Interim Safety and Efficacy Results from a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29519807" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the humanβ-globin locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26104837" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : HbA2 : biology, clinical relevance and a possible target for ameliorating sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25042611" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The genetics of hemoglobin A2 regulation in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34046885" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Delta-globin gene expression improves sickle cell disease in a humanised mouse model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36399071" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Kruppel-like factor 1-GATA1 fusion protein improves the sickle cell disease phenotype in mice both in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36399071" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Kruppel-like factor 1-GATA1 fusion protein improves the sickle cell disease phenotype in mice both in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32396618" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34898140" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33891501" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : After Analysis, Bluebird Bio Says Vector "Very Unlikely" Cause of Acute Myeloid Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34115136" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31371806" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27062606" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
